Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies

Launched by UNIVERSITY OF PITTSBURGH · Apr 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how changes in liver size, which can occur at different times of the day or based on whether a person has eaten, can impact the planning and delivery of a specific type of radiation treatment called Stereotactic Body Radiation Therapy (SBRT) for people with upper abdominal cancers. The goal is to understand if these natural changes in liver volume could lead to errors in how much radiation is safely delivered to the liver, which is important for preventing potential side effects.

To qualify for this study, participants should be between the ages of 65 and 74 and have a diagnosis of upper abdominal cancer, such as pancreatic or liver cancer, or cancer that has spread to the upper abdomen. Participants should not have received prior radiation therapy to the liver or have certain health conditions that would prevent them from undergoing the necessary imaging tests. Those who join the trial can expect to undergo tests to measure liver size and learn more about how these factors influence their treatment. This study aims to improve the safety and effectiveness of radiation therapy for patients with upper abdominal malignancies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Have primary upper abdominal (pancreatic, bile duct, liver) cancer or upper abdominal metastases (liver, adrenal, upper abdominal lymph nodes) planned to undergo SBRT.
• Exclusion Criteria:
• • Had prior Radiation Therapy to the liver
• • Contraindication to receipt of iodinated IV contrast for CT (such as renal insufficiency or allergy that cannot be overcome by premedication)
• • Pregnancy/lactation OR woman of childbearing potential who is unable or unwilling to use adequate contraception during Radiation Therapy.
• • Inability to fast.